Please sign in to follow a disease.
Acromegaly
MONDO:0019933Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
Also known as: Growth hormone excess, pituitary giant, somatotroph adenoma
29 clinical trials for this condition and its sub-types, 29 tagged with Acromegaly itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug combo aims to tame acromegaly hormone levels
Disease control Stopped earlyThis phase 2 trial tests whether adding ALXN2420 (a growth hormone blocker) to standard acromegaly treatment can lower IGF-1 levels more than placebo. About 60 adults with acromegaly who are already on a stable dose of somatostatin analogs will receive either ALXN2420 or placebo …
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill shows promise for controlling acromegaly Long-Term
Disease control Stopped earlyThis study looks at the long-term safety and effectiveness of an oral medication called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. About 43 adults who finished a previous related study will take the drug and be monitored for …
Phase 2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a pill replace needles for acromegaly?
Disease control Stopped earlyThis study tests an oral drug called paltusotine for people with acromegaly, a condition where the body makes too much growth hormone. Participants had their disease under control with standard injections and were randomly assigned to receive either paltusotine or a placebo. The …
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill could tame rare growth disorder without surgery
Disease control Stopped earlyThis study tests an oral drug called paltusotine in 111 adults with acromegaly, a condition causing abnormal growth due to high hormone levels. Participants are not currently on other treatments. The main goal is to see if the drug safely lowers insulin-like growth factor-1 (IGF-…
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New 12-Week hormone therapy studied for rare tumors
Disease control Stopped earlyThis early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to me…
Phase 1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC